Effect of Sacubitril-Valsartan on Cardiac Structure and Function
Effect of Sacubitril-Valsartan on Cardiac Structure and Function in Adults With Congenital Heart Disease
Mayo Clinic
45 participants
Feb 3, 2025
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to compare changes in cardiac structure and function, biomarkers, and patient reported outcomes between adults with congenital heart disease (ACHD) randomized to angiotensin receptor-neprilysin inhibitor (ARNI) therapy vs placebo.
Eligibility
Inclusion Criteria2
- Congenital Heart Disease Diagnosis
- Age 18 or Older
Exclusion Criteria18
- Stage IV chronic kidney disease defined as creatinine clearance <30 ml/min
- Hyperkalemia defined as serum potassium >5.2 mmol/l,
- Hypotension defined as systolic blood pressure <100 mmHg,
- History of angioedema related to previous ACE or ARB therapy
- Patients diagnosed with diabetes using Aliskiren,
- Pregnancy.
- Drug Therapies
- Amifostine
- Droperidol
- Dantrolene
- CYP3A4 Inhibitors
- Obinutuzumab
- Aliskiren
- Lithium
- Sparsentan
- ACE inhibitor
- ARB
- ARNI
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Patients will take a 24/26 mg dose orally, twice daily, for weeks 1 and 2, 49/51 mg orally, twice daily, for weeks 3 and 4, and 97/103 mg orally twice daily, for the remaining 48 weeks (total duration: 52 weeks).
Patients taking placebo tablets will take 1 tablet orally, twice daily
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06693674